US2022296778A1PendingUtilityA1
Allogeneic microvascular tissue for soft tissue treatments
Est. expiryMar 18, 2031(~4.7 yrs left)· nominal 20-yr term from priority
A61L 27/56A61L 27/3662A61L 27/3691A61L 27/3834A61L 27/3683A61L 27/54A61K 35/28A61K 35/35A61L 27/3625A61L 2430/06A61K 35/12C12N 5/0653A61L 27/3604A61L 2300/64A61L 2430/10A61L 27/3687
76
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are products and methods for treating soft tissue injuries. The provided methods include the production of processed or cryopreserved microvascular tissue. Also provided are products and methods of using processed or cryopreserved microvascular tissue for the treatment of soft tissue injuries.
Claims
exact text as granted — not AI-modified1 - 18 . (canceled)
19 . A composition comprising a plurality of nonviable progenitor cells with tissue healing activity.
20 . The composition of claim 19 , wherein less than 50% of the progenitor cells are viable.
21 . The composition of claim 19 , wherein less than 30% of the progenitor cells are viable.
22 . The composition of claim 19 , wherein less than 10% of the progenitor cells are viable.
23 . The composition of claim 19 , wherein the progenitor cells are isolated from microvascular tissue.
24 . The composition as in one of the claims 19 - 22 , wherein the progenitor cells have been dried.
25 . The composition as in one of the claims 19 - 22 , wherein the progenitor cells have been cryopreserved.
26 . The composition as in one of the claims 19 - 22 , wherein the progenitor cells have been lyophilized.
27 . The composition of claim 19 , wherein some of the progenitor cells have intact cell membranes.
28 . The composition of claim 19 , wherein the tissue healing activity includes both hard and soft tissues.
29 . The composition of claim 28 , wherein the tissue healing activity includes healing of bone, tendon, ligament and skin defects or disorders.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.